Shots:

• The FDA has granted FTD to LYS-GM101 for the Treatment of GM1 Gangliosidosis. The company has recently initiated an adaptative-design clinical trial evaluating the efficacy & safety of LYS-GM101 in 16 patients with GM1 gangliosidosis across the US & EU
• The P-II/III clinical trial for MPS IIIA is ongoing- following collaboration with Sarepta whereas Sarepta will hold exclusive commercial rights to LYS-SAF302 in the US & EU & Lysogene will maintain commercial exclusivity in the EU
• The FDA has granted RPDD in 2016 & ODD in 2017 for LYS-GM101. Lysogene has also entered into an exclusive WW license agreement with SATT Conectus for LYS-GM101 to treat Fragile X syndrome

  Ref: Businesswire | Image: Lysogene